文献速递产科母胎医学

妊娠期间或妊娠前诊断霍奇金淋巴瘤后的母体与围产期结局:一项系统评价

Maternal and perinatal outcomes following a diagnosis of Hodgkin lymphoma during or prior to pregnancy: A systematic review.
PubMed 文献 · BJOG · 2022-12-12

该系统评价检索截至2022年6月的多个数据库,纳入33项研究,比较妊娠前或妊娠期间诊断霍奇金淋巴瘤(HL)的孕妇与一般孕妇的母体及围产期结局。多数不良妊娠结局未显著增加,但妊娠期间诊断HL者输血和静脉血栓栓塞(VTE)的比值比显著升高,贫血比例也升高;证据确定性为低至极低。

要点

  • 妊娠前或妊娠期间诊断HL的孕妇,多数不良妊娠结局未较一般孕妇显著增加。
  • 妊娠期间诊断HL者,输血(aOR 1.38,95% CI 1.05-1.82)和VTE(aOR 7.93,95% CI 2.97-21.22)风险显著升高。
  • 妊娠期间诊断HL者贫血比例为69%(95% CI 57%-80%),高于一般孕妇的4%(95% CI 4%-5%)。

核心结论

  • 妊娠前或妊娠期间诊断HL的孕妇,多数不良妊娠结局的发生率未较一般孕妇显著增加。
  • 妊娠期间诊断HL者早产率可能更高,VTE、贫血和输血的可能性增加;但研究数量少且GRADE证据确定性为低至极低,无法得出确切结论。

研究设计与样本

  • 系统评价,检索PubMed/Medline、Cochrane Library、Scopus、Embase和Science Direct自建库至2022年6月,并手工检索参考文献列表。
  • 两名评价员独立筛选文献、提取数据并评估研究质量;共纳入33项研究(初检5527项)。
  • 将既往或当前诊断HL的孕妇结局分别与从未诊断HL的孕妇比较;在数据允许时对优势比和比例进行Meta分析,采用GRADE框架评定证据确定性。

主要发现

  • 妊娠前诊断HL组与妊娠期间诊断HL组的先天畸形aOR分别为1.7(95% CI 0.9-3.1)和1.84(95% CI 0.81-4.15),均无统计学意义。
  • 妊娠前诊断HL组与妊娠期间诊断HL组的早产aOR分别为0.99(95% CI 0.65-1.51)和6.74(95% CI 0.52-88.03),均无统计学意义。
  • 妊娠前诊断HL组与妊娠期间诊断HL组的流产aOR分别为0.78(95% CI 0.55-1.10)和0.38(95% CI 0.05-2.72),均无统计学意义。
  • 妊娠期间诊断HL组输血aOR为1.38(95% CI 1.05-1.82),VTE的aOR为7.93(95% CI 2.97-21.22),均有统计学意义。
  • 妊娠期间诊断HL组贫血比例为69%(95% CI 57%-80%),一般孕妇为4%(95% CI 4%-5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究数量少。
  • GRADE证据确定性为低至极低,无法得出确切结论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The initial peak incidence of Hodgkin lymphoma (HL) occurs during reproductive years. OBJECTIVES: Synthesise published literature on the relationship between HL and maternal and perinatal outcomes. SEARCH STRATEGY: Systematic search of PubMed/Medline, Cochrane Library, Scopus, Embase and Science Direct from inception to June 2022, supplemented by hand-searching reference lists. SELECTION CRITERIA: Two reviewers independently reviewed titles, abstracts and full-text articles. Published studies containing original data were eligible. DATA COLLECTION AND ANALYSIS: Two reviewers independently extracted data and appraised study quality. Outcomes for pregnant women with a previous/current diagnosis of HL were compared separately with women never diagnosed with HL. Where data permitted, meta-analyses of odds ratios and proportions were performed. Certainty of evidence was determined using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. MAIN RESULTS: Of the 5527 studies identified, 33 met the inclusion criteria. In the groups with HL before pregnancy and HL during pregnancy, adjusted odds ratios were not statistically significant for congenital malformation (aOR 1.7, 95% CI 0.9-3.1, and aOR 1.84, 95% CI 0.81-4.15, respectively), preterm birth (PTB) (aOR 0.99, 95% CI 0.65-1.51, and aOR 6.74, 95% CI 0.52-88.03, respectively) and miscarriage (aOR 0.78, 95% CI 0.55-1.10, and aOR 0.38, 95% CI 0.05-2.72, respectively). The aORs for all other outcomes were not statistically significant, except for blood transfusion (aOR 1.38, 95% CI 1.05-1.82) and venous thromboembolism (VTE) (aOR 7.93, 95% CI 2.97-21.22) in the group for HL during pregnancy. The proportion of anaemia was also increased in this group (69%, 95% CI 57%-80% vs 4%, 95% CI 4%-5%, respectively). The GRADE certainty of findings ranged from low to very low. CONCLUSIONS: Rates of most adverse pregnancy outcomes among women with a previous/current HL diagnosis are not increased significantly compared with the general pregnant population. Women with HL diagnosed during pregnancy may have a higher PTB rate and increased likelihood of VTE, anaemia and blood transfusion; however, small study numbers and the low to very low GRADE certainty of findings preclude firm conclusions.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Houlihan OA, Buckley D, Maher GM, et al. Maternal and perinatal outcomes following a diagnosis of Hodgkin lymphoma during or prior to pregnancy: A systematic review. BJOG. 2022. PMID: 36424902. doi:10.1111/1471-0528.17347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。